JP2020183389A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020183389A5 JP2020183389A5 JP2020108569A JP2020108569A JP2020183389A5 JP 2020183389 A5 JP2020183389 A5 JP 2020183389A5 JP 2020108569 A JP2020108569 A JP 2020108569A JP 2020108569 A JP2020108569 A JP 2020108569A JP 2020183389 A5 JP2020183389 A5 JP 2020183389A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- gdf11
- receptor type
- activin receptor
- activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003112 inhibitor Substances 0.000 claims 54
- 102000018918 Activin Receptors Human genes 0.000 claims 53
- 108010052946 Activin Receptors Proteins 0.000 claims 53
- 102100040898 Growth/differentiation factor 11 Human genes 0.000 claims 51
- 101000893545 Homo sapiens Growth/differentiation factor 11 Proteins 0.000 claims 51
- 230000000694 effects Effects 0.000 claims 43
- 239000012634 fragment Substances 0.000 claims 20
- 239000008194 pharmaceutical composition Substances 0.000 claims 19
- 210000001519 tissue Anatomy 0.000 claims 14
- 101100437153 Rattus norvegicus Acvr2b gene Proteins 0.000 claims 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims 9
- 229920001184 polypeptide Polymers 0.000 claims 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims 8
- 210000003743 erythrocyte Anatomy 0.000 claims 7
- 230000001404 mediated effect Effects 0.000 claims 6
- 230000011664 signaling Effects 0.000 claims 6
- 208000007502 anemia Diseases 0.000 claims 3
- 230000003247 decreasing effect Effects 0.000 claims 3
- 210000004005 intermediate erythroblast Anatomy 0.000 claims 2
- 108010059616 Activins Proteins 0.000 claims 1
- 102100026818 Inhibin beta E chain Human genes 0.000 claims 1
- 208000008601 Polycythemia Diseases 0.000 claims 1
- 239000000488 activin Substances 0.000 claims 1
- 208000005980 beta thalassemia Diseases 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 210000003924 normoblast Anatomy 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 210000000952 spleen Anatomy 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261718126P | 2012-10-24 | 2012-10-24 | |
| US61/718,126 | 2012-10-24 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018131226A Division JP2018184428A (ja) | 2012-10-24 | 2018-07-11 | 貧血の治療に使用するためのバイオマーカー |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020183389A JP2020183389A (ja) | 2020-11-12 |
| JP2020183389A5 true JP2020183389A5 (cg-RX-API-DMAC7.html) | 2021-02-25 |
| JP7146850B2 JP7146850B2 (ja) | 2022-10-04 |
Family
ID=50545462
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015539750A Active JP6401171B2 (ja) | 2012-10-24 | 2013-10-23 | 貧血の治療に使用するためのバイオマーカー |
| JP2018131226A Pending JP2018184428A (ja) | 2012-10-24 | 2018-07-11 | 貧血の治療に使用するためのバイオマーカー |
| JP2020108569A Active JP7146850B2 (ja) | 2012-10-24 | 2020-06-24 | 貧血の治療に使用するためのバイオマーカー |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015539750A Active JP6401171B2 (ja) | 2012-10-24 | 2013-10-23 | 貧血の治療に使用するためのバイオマーカー |
| JP2018131226A Pending JP2018184428A (ja) | 2012-10-24 | 2018-07-11 | 貧血の治療に使用するためのバイオマーカー |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20150276766A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP2912462B1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP6401171B2 (cg-RX-API-DMAC7.html) |
| CN (2) | CN113604550A (cg-RX-API-DMAC7.html) |
| AU (3) | AU2013334659B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2889209C (cg-RX-API-DMAC7.html) |
| ES (2) | ES3031001T3 (cg-RX-API-DMAC7.html) |
| IL (3) | IL267663B (cg-RX-API-DMAC7.html) |
| SA (1) | SA515360337B1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014066486A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105001320A (zh) | 2005-11-23 | 2015-10-28 | 阿塞勒隆制药公司 | Activin-ActRIIa拮抗剂及其促进骨骼生长的应用 |
| US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
| US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
| CN101835485B (zh) | 2007-02-01 | 2016-10-26 | 阿塞勒隆制药公司 | 活化素-actriia拮抗剂及在治疗或预防乳腺癌中的用途 |
| TW201940502A (zh) | 2007-02-02 | 2019-10-16 | 美商艾瑟勒朗法瑪公司 | 衍生自ＡｃｔＲＩＩＢ的變體與其用途 |
| JP5574711B2 (ja) | 2007-02-09 | 2014-08-20 | アクセルロン ファーマ， インコーポレイテッド | 癌患者における骨成長を促進するためのアクチビン−ａｃｔｒｉｉａアンタゴニストおよびその使用 |
| EP3243524A1 (en) | 2007-09-18 | 2017-11-15 | Acceleron Pharma Inc. | Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion |
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| WO2010019261A1 (en) | 2008-08-14 | 2010-02-18 | Acceleron Pharma Inc. | Use of gdf traps to increase red blood cell levels |
| BRPI1010704B1 (pt) | 2009-06-12 | 2021-12-14 | Acceleron Pharma Inc | Polipeptídeo recombinante, proteína de fusão recombinante, preparação farmacêutica e uso da mesma |
| JP6267425B2 (ja) | 2009-11-17 | 2018-01-24 | アクセルロン ファーマ， インコーポレイテッド | 筋ジストロフィー治療のためのユートロフィン誘導に関するａｃｔｒｉｉｂタンパク質およびその改変体およびその使用 |
| AU2011326586A1 (en) | 2010-11-08 | 2013-05-30 | Acceleron Pharma, Inc. | ActRIIA binding agents and uses thereof |
| NZ707477A (en) | 2012-11-02 | 2019-09-27 | Celgene Corp | Activin-actrii antagonists and uses for treating bone and other disorders |
| BR112016024319B1 (pt) * | 2014-04-18 | 2024-01-23 | Acceleron Pharma Inc | USO DE UMA COMPOSIÇÃO COMPREENDENDO UM ANTAGONISTA DE ActRII PARA A FABRICAÇÃO DE UM MEDICAMENTO PARA TRATAR OU PREVINIR UMA COMPLICAÇÃO DE ANEMIA FALCIFORME |
| AP2017009674A0 (en) | 2014-06-13 | 2017-01-31 | Acceleron Pharma Inc | Methods and compositions for treating ulcers |
| MA41052A (fr) * | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
| JP6768651B2 (ja) * | 2014-11-24 | 2020-10-14 | ソマロジック, インコーポレイテッドSomaLogic, Inc. | 増殖分化因子１１と結合するための核酸化合物 |
| JP2018501307A (ja) * | 2014-12-03 | 2018-01-18 | セルジーン コーポレイション | アクチビン−ＡｃｔＲＩＩアンタゴニスト及び貧血を治療するための使用 |
| JP6959487B2 (ja) | 2015-04-22 | 2021-11-02 | バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． | 筋消耗疾患治療用の新規なハイブリッドａｃｔｒｉｉｂリガンド捕集タンパク質 |
| KR102640198B1 (ko) * | 2015-05-13 | 2024-02-23 | 셀진 코포레이션 | Actrii 리간드 트랩을 사용한 베타-탈라세미아의 치료 |
| WO2016187378A1 (en) * | 2015-05-20 | 2016-11-24 | Celgene Corporation | In vitro cell culture methods for beta-thalassemia using activin type ii receptor ligand traps |
| US11123430B2 (en) | 2015-11-04 | 2021-09-21 | Acceleron Pharma Inc. | Methods for increasing red blood cell levels and treating ineffective erythropoiesis |
| CN105738614B (zh) * | 2016-02-23 | 2017-12-05 | 山东大学 | 一种应用流式细胞仪分析评价小鼠骨髓红细胞生成功能的方法 |
| RS65735B1 (sr) | 2016-07-27 | 2024-08-30 | Acceleron Pharma Inc | Kompozicije za upotrebu u lečenju mijelofibroze |
| JOP20190085A1 (ar) | 2016-10-20 | 2019-04-17 | Biogen Ma Inc | طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة |
| CA3177632A1 (en) | 2020-05-15 | 2021-11-18 | Melih ACAR | Methods and compositions for treating anemia using actriib ligand traps and mtor inhibitors |
| US12186370B1 (en) | 2020-11-05 | 2025-01-07 | Celgene Corporation | ACTRIIB ligand trap compositions and uses thereof |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1987005330A1 (en) | 1986-03-07 | 1987-09-11 | Michel Louis Eugene Bergh | Method for enhancing glycoprotein stability |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5096815A (en) | 1989-01-06 | 1992-03-17 | Protein Engineering Corporation | Generation and selection of novel dna-binding proteins and polypeptides |
| US5198346A (en) | 1989-01-06 | 1993-03-30 | Protein Engineering Corp. | Generation and selection of novel DNA-binding proteins and polypeptides |
| DK0776337T3 (da) * | 1994-07-08 | 2005-12-12 | Univ Johns Hopkins Med | Vækstdifferentieringsfaktor-11 |
| US6891082B2 (en) * | 1997-08-01 | 2005-05-10 | The Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a truncated activintype II receptor |
| CA2302525A1 (en) | 1997-08-29 | 1999-03-04 | Human Genome Sciences, Inc. | Follistatin-3 |
| EP1356075A4 (en) | 2000-10-16 | 2005-04-13 | Compound Therapeutics Inc | PROTEIN EQUIPMENT FOR ANTIBODY MIMETICS AND OTHER TIE PROTEINS |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| TWI329129B (en) * | 2001-02-08 | 2010-08-21 | Wyeth Corp | Modified and stabilized gdf propeptides and uses thereof |
| ATE472609T1 (de) | 2001-04-26 | 2010-07-15 | Amgen Mountain View Inc | Kombinatorische bibliotheken von monomerdomänen |
| PL374966A1 (en) * | 2002-02-21 | 2005-11-14 | Wyeth | Follistatin domain containing proteins |
| US20070135336A1 (en) | 2003-09-15 | 2007-06-14 | De Kretser David | Follistatin isoforms and uses thereof |
| AU2005266875B2 (en) | 2004-07-23 | 2012-07-26 | Acceleron Pharma Inc. | ActRII receptor polypeptides, methods and compositions |
| JP2008520207A (ja) | 2004-11-16 | 2008-06-19 | アヴィディア リサーチ インスティテュート | タンパク質骨格およびその使用 |
| US8067562B2 (en) * | 2005-11-01 | 2011-11-29 | Amgen Inc. | Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1 |
| WO2008030367A2 (en) | 2006-09-01 | 2008-03-13 | The General Hospital Corporation | Selective myostatin inhibitors |
| AU2007334333B2 (en) * | 2006-12-18 | 2013-05-30 | Acceleron Pharma Inc. | Activin-ActRII antagonists and uses for increasing red blood cell levels |
| TW201940502A (zh) | 2007-02-02 | 2019-10-16 | 美商艾瑟勒朗法瑪公司 | 衍生自ＡｃｔＲＩＩＢ的變體與其用途 |
| EP2315602A4 (en) * | 2008-06-26 | 2011-11-02 | Acceleron Pharma Inc | METHOD OF DOSING AN ACTRIIB ANTAGONIST AND MONITORING TREATED PATIENTS |
| WO2010019261A1 (en) | 2008-08-14 | 2010-02-18 | Acceleron Pharma Inc. | Use of gdf traps to increase red blood cell levels |
| US8216997B2 (en) * | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| DK2424895T3 (en) | 2009-04-27 | 2017-12-18 | Novartis Ag | Compositions and Methods for Increasing Muscle Growth |
| CN105535938B (zh) * | 2009-08-13 | 2022-04-26 | 阿塞勒隆制药公司 | Gdf捕获物和促红细胞生成素受体激活剂联合应用以增加红细胞水平 |
| AU2011326586A1 (en) * | 2010-11-08 | 2013-05-30 | Acceleron Pharma, Inc. | ActRIIA binding agents and uses thereof |
-
2013
- 2013-10-23 CN CN202110622231.6A patent/CN113604550A/zh active Pending
- 2013-10-23 IL IL267663A patent/IL267663B/en unknown
- 2013-10-23 IL IL290653A patent/IL290653B2/en unknown
- 2013-10-23 WO PCT/US2013/066350 patent/WO2014066486A2/en not_active Ceased
- 2013-10-23 EP EP13848471.2A patent/EP2912462B1/en active Active
- 2013-10-23 EP EP19184182.4A patent/EP3608419B1/en active Active
- 2013-10-23 CA CA2889209A patent/CA2889209C/en active Active
- 2013-10-23 AU AU2013334659A patent/AU2013334659B2/en active Active
- 2013-10-23 US US14/438,120 patent/US20150276766A1/en not_active Abandoned
- 2013-10-23 ES ES19184182T patent/ES3031001T3/es active Active
- 2013-10-23 ES ES13848471T patent/ES2753811T3/es active Active
- 2013-10-23 JP JP2015539750A patent/JP6401171B2/ja active Active
- 2013-10-23 CN CN201380067792.8A patent/CN104968801B/zh active Active
-
2015
- 2015-04-21 IL IL238414A patent/IL238414B/en active IP Right Grant
- 2015-04-23 SA SA515360337A patent/SA515360337B1/ar unknown
-
2018
- 2018-03-09 US US15/916,634 patent/US20190049469A1/en not_active Abandoned
- 2018-07-11 JP JP2018131226A patent/JP2018184428A/ja active Pending
-
2019
- 2019-06-12 AU AU2019204098A patent/AU2019204098B2/en active Active
-
2020
- 2020-06-24 JP JP2020108569A patent/JP7146850B2/ja active Active
-
2021
- 2021-09-21 AU AU2021236465A patent/AU2021236465B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020183389A5 (cg-RX-API-DMAC7.html) | ||
| JP2016500698A5 (cg-RX-API-DMAC7.html) | ||
| Hashizume et al. | Tocilizumab, a humanized anti-interleukin-6 receptor antibody, improved anemia in monkey arthritis by suppressing IL-6-induced hepcidin production | |
| JP2018184428A5 (cg-RX-API-DMAC7.html) | ||
| Totsuka et al. | RANK-RANKL signaling pathway is critically involved in the function of CD4+ CD25+ regulatory T cells in chronic colitis | |
| Al Husseini et al. | Thyroid hormone is highly permissive in angioproliferative pulmonary hypertension in rats | |
| BR112021010789A2 (pt) | Anticorpos anti-il-36r para o tratamento de pustulose palmoplantar | |
| HU206988B (en) | Process for producing pharmaceutical composition comprising gamma-interferon as active ingredient | |
| US20210196822A1 (en) | Treatment of triple negative breast cancer with targeted tgf-b inhibition | |
| Bruggers et al. | Acquired von Willebrand disease in twins with autoimmune hypothyroidism: response to desmopressin and L-thyroxine therapy | |
| JP2017031209A (ja) | アタシセプトなどのＴＡＣＩ−Ｉｇ融合タンパク質を用いた自己免疫疾患を治療するための投薬法 | |
| Baez-Villasenor et al. | The blood picture in Addison’s disease | |
| WO2022235636A1 (en) | Combination therapy of carboplatin and napi2b-targeted polymer antibody-drug conjugate for the treatment of ovarian cancer | |
| KR20230086674A (ko) | 파킨슨 질환의 치료 | |
| EP1539247A2 (en) | Alpha 5 beta 1 and its ability to regulate the cell survival pathway | |
| CN120112294A (zh) | 通过施用(R)-2-[3-[4-氨基-3-(2-氟-4-苯氧基-苯基)吡唑并[3,4-d]嘧啶-1-基]哌啶-1-羰基]-4-甲基-4-[4-(氧杂环丁-3-基)哌嗪-1-基]戊-2-烯腈治疗免疫性血小板减少症的方法 | |
| WO2023211864A1 (en) | Use of lat1 inhibitors to treat obesity | |
| EP1517703B1 (en) | Placental growth factor as a target for the treatment of osteoporosis | |
| WO2012033518A1 (en) | Methods and compositions for treating metabolic disorders | |
| Agafina et al. | Efficacy and safety of trimodulin in patients with severe COVID-19: results from a randomised, placebo-controlled, double-blind, multicentre, phase II trial (ESsCOVID) | |
| US12454573B2 (en) | Dosages of emactuzumab | |
| JP7737395B2 (ja) | サイトカインストーム症候群の治療のためのペプチド | |
| Schmid et al. | New strategies for managing anemia of chronic kidney disease | |
| Richie et al. | Sickle cell trait: forgotten cause of hematuria in white patients | |
| JP2016169205A (ja) | 汗分泌促進剤及び該汗分泌促進剤を含有するドライスキンの予防薬又は治療薬 |